Table 2 Characteristics of aGVHD after preemptive IFN-α treatment.

From: Preemptive interferon-α treatment could protect against relapse and improve long-term survival of ALL patients after allo-HSCT

Characteristics of aGVHD

IFN-α group (n = 68)

Time from aGVHD to immunotherapy, days (range)

12 (1–64)

Severity of aGVHD, n (%)

 None

58 (85.3)

 Grade I

3 (4.4)

 Grade II

5 (7.4)

 Grade III

2 (2.9)

Site of aGVHD, n (%)

 Skin

9 (13.2)

 Liver

0 (0.0)

 Gut

4 (5.9)

Number of sites, n (%)

 0

58 (85.3)

 1

7 (10.3)

 2

3 (4.4)

  1. Data was present as n (%) or median (range).
  2. aGVHD acute graft-versus-host disease, IFN-α interferon-α.
Back to article page